You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 25, 2024

HALOBETASOL PROPIONATE - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for halobetasol propionate and what is the scope of patent protection?

Halobetasol propionate is the generic ingredient in five branded drugs marketed by Padagis Israel, Mayne Pharma, Cosette, Fougera Pharms, Taro, Sun Pharm Inds Inc, Bausch, Mical Pharms, Encube, and Quagen, and is included in nineteen NDAs. There are thirteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Halobetasol propionate has seventy-five patent family members in twenty-seven countries.

There are nine drug master file entries for halobetasol propionate. Nine suppliers are listed for this compound. There are two tentative approvals for this compound.

Drug Prices for HALOBETASOL PROPIONATE

See drug prices for HALOBETASOL PROPIONATE

Recent Clinical Trials for HALOBETASOL PROPIONATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Dermatology Consulting Services, PLLCPhase 4
Icahn School of Medicine at Mount SinaiPhase 3
Citius Pharmaceuticals, Inc.Phase 2

See all HALOBETASOL PROPIONATE clinical trials

Generic filers with tentative approvals for HALOBETASOL PROPIONATE
Applicant Application No. Strength Dosage Form
⤷  Subscribe⤷  SubscribeUNKNOWNUNKNOWN
⤷  Subscribe⤷  Subscribe0.01%;0.045%LOTION;TOPICAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for HALOBETASOL PROPIONATE
Paragraph IV (Patent) Challenges for HALOBETASOL PROPIONATE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
LEXETTE Topical Foam halobetasol propionate 0.05% 210566 1 2021-01-28
BRYHALI Lotion halobetasol propionate 0.01% 209355 1 2019-05-15
ULTRAVATE Lotion halobetasol propionate 0.05% 208183 1 2018-01-24

US Patents and Regulatory Information for HALOBETASOL PROPIONATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bausch DUOBRII halobetasol propionate; tazarotene LOTION;TOPICAL 209354-001 Apr 25, 2019 RX Yes Yes ⤷  Subscribe ⤷  Subscribe Y ⤷  Subscribe
Bausch BRYHALI halobetasol propionate LOTION;TOPICAL 209355-001 Nov 6, 2018 RX Yes Yes ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Bausch DUOBRII halobetasol propionate; tazarotene LOTION;TOPICAL 209354-001 Apr 25, 2019 RX Yes Yes ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Bausch DUOBRII halobetasol propionate; tazarotene LOTION;TOPICAL 209354-001 Apr 25, 2019 RX Yes Yes ⤷  Subscribe ⤷  Subscribe Y ⤷  Subscribe
Bausch BRYHALI halobetasol propionate LOTION;TOPICAL 209355-001 Nov 6, 2018 RX Yes Yes ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Sun Pharm Inds Inc ULTRAVATE halobetasol propionate CREAM;TOPICAL 019967-001 Dec 27, 1990 DISCN Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Cosette HALOBETASOL PROPIONATE halobetasol propionate CREAM;TOPICAL 078162-001 Apr 24, 2007 AB RX No Yes ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for HALOBETASOL PROPIONATE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sun Pharm Inds Inc ULTRAVATE halobetasol propionate CREAM;TOPICAL 019967-001 Dec 27, 1990 ⤷  Subscribe ⤷  Subscribe
Sun Pharm Inds Inc ULTRAVATE halobetasol propionate OINTMENT;TOPICAL 019968-001 Dec 17, 1990 ⤷  Subscribe ⤷  Subscribe
Bausch BRYHALI halobetasol propionate LOTION;TOPICAL 209355-001 Nov 6, 2018 ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for HALOBETASOL PROPIONATE

Country Patent Number Title Estimated Expiration
Slovenia 2643002 ⤷  Subscribe
Eurasian Patent Organization 201891351 ВСПЕНИВАЕМАЯ КОМПОЗИЦИЯ ГАЛОБЕТАЗОЛА И СПОСОБ ЕЁ ПРИМЕНЕНИЯ ⤷  Subscribe
Singapore 11201502931Y TOPICAL STEROID COMPOSITION AND METHOD ⤷  Subscribe
Portugal 2643002 ⤷  Subscribe
New Zealand 610659 Pharmaceutical formulations containing corticosteroids for topical administration ⤷  Subscribe
China 108601733 卤倍他索泡沫组合物及其使用方法 (HALOBETASOL FOAM COMPOSITION AND METHOD OF USE THEREOF) ⤷  Subscribe
European Patent Office 2643002 FORMULATIONS PHARMACEUTIQUES CONTENANT DES CORTICOSTÉROÏDES POUR ADMINISTRATION TOPIQUE (PHARMACEUTICAL FORMULATIONS CONTAINING CORTICOSTEROIDS FOR TOPICAL ADMINISTRATION) ⤷  Subscribe
>Country >Patent Number >Title >Estimated Expiration

HALOBETASOL PROPIONATE Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory of Halobetasol Propionate

Market Overview

Halobetasol propionate, a potent topical corticosteroid, is used primarily for the treatment of plaque psoriasis and other skin conditions. The market for this drug is experiencing significant growth, driven by increasing demand for effective treatments for dermatological conditions.

Market Size and Growth

The global halobetasol propionate market was valued at US$ 39 million in 2023 and is projected to reach US$ 54 million by 2030, growing at a Compound Annual Growth Rate (CAGR) of 4.9% during the forecast period of 2024-2030[1][4].

Segmentation

The market is segmented based on type and application. The types include 15g, 30g, and other formulations, while the applications are categorized into hospital, clinic, and other settings[1][4].

Geographical Distribution

The market is geographically segmented into North America, Europe, Asia-Pacific, South America, and the Middle East & Africa. Each region is experiencing varying growth rates, with Asia-Pacific showing significant potential due to a large patient population and increasing healthcare expenditure[4].

Key Players

The market is dominated by several key players, including ULTRAVATE, LEXETTE, Glenmark Pharma, Sun Pharma, BRYHALI, PERRIGO, Duobrii, STERLING, Midas Pharma, Pfizer, Taro Pharmaceuticals, Glenwood Pharmaceuticals, and Fougera Pharmaceuticals. These companies are investing heavily in research and development, marketing, and distribution to capture a larger market share[1][4].

Product Launches and Innovations

Recent product launches have contributed significantly to the market's growth. For example, Mayne Pharma's launch of LEXETTE™ (halobetasol propionate) Foam 0.05% in the United States in 2019 marked a significant milestone. LEXETTE received FDA approval with three years of marketing exclusivity, positioning it strongly in the US$600 million potent topical corticosteroid market[2].

Market Drivers

Several factors are driving the growth of the halobetasol propionate market:

  • Increasing Prevalence of Dermatological Conditions: Plaque psoriasis affects approximately 7.5 million Americans, and potent topical corticosteroids are prescribed to about 80% of these patients[2].
  • Advancements in Formulations: New formulations such as foams and lotions are enhancing patient compliance and efficacy, contributing to market growth.
  • Growing Healthcare Expenditure: Increasing healthcare spending in various regions is enabling more patients to access these treatments.

Market Restraints

Despite the growth, there are several restraints to consider:

  • Side Effects and Safety Concerns: Topical corticosteroids, including halobetasol propionate, can have adverse effects such as skin thinning, adrenal suppression, and systemic exposure, which may limit their use[5].
  • Regulatory Hurdles: Strict regulatory approvals and the need for extensive clinical trials can slow down the introduction of new products.

Competitive Landscape

The competitive landscape is intense, with multiple players vying for market share. Companies are focusing on innovative formulations, direct-to-consumer advertising, and expanding their sales force capabilities to stay competitive. For instance, Bausch Health is investing in direct-to-consumer advertising and new sales force capabilities, leveraging artificial intelligence and machine learning to enhance their market presence[3].

Financial Performance

The financial performance of companies involved in the halobetasol propionate market is robust. For example, the potent topical corticosteroid market, which includes halobetasol propionate, generates significant revenue, with 8 million prescriptions written annually in the United States alone[2].

Regional Growth

North America is a major market for halobetasol propionate, driven by the high prevalence of psoriasis and other skin conditions. However, the Asia-Pacific region is expected to show substantial growth due to increasing healthcare awareness and expenditure[4].

Future Outlook

The future outlook for the halobetasol propionate market is positive, with sustained growth expected through 2030. The market will continue to be driven by the increasing demand for effective treatments for dermatological conditions, advancements in formulations, and expanding healthcare access in various regions.

Key Takeaways

  • The global halobetasol propionate market is projected to grow from US$ 39 million in 2023 to US$ 54 million by 2030 at a CAGR of 4.9%.
  • The market is segmented by type (15g, 30g, other) and application (hospital, clinic, other).
  • Key players include ULTRAVATE, LEXETTE, Glenmark Pharma, and others.
  • New product launches and innovations, such as LEXETTE Foam, are driving market growth.
  • Increasing prevalence of dermatological conditions and advancements in formulations are major market drivers.
  • Regulatory hurdles and side effects are significant restraints.

Frequently Asked Questions (FAQs)

1. What is the current market size of halobetasol propionate?

The global halobetasol propionate market was valued at US$ 39 million in 2023[1].

2. What is the expected growth rate of the halobetasol propionate market?

The market is expected to grow at a CAGR of 4.9% from 2024 to 2030[1].

3. Who are the key players in the halobetasol propionate market?

Key players include ULTRAVATE, LEXETTE, Glenmark Pharma, Sun Pharma, BRYHALI, PERRIGO, Duobrii, STERLING, Midas Pharma, Pfizer, Taro Pharmaceuticals, Glenwood Pharmaceuticals, and Fougera Pharmaceuticals[1][4].

4. What are the primary applications of halobetasol propionate?

The primary applications are in the treatment of plaque psoriasis and other skin conditions, with usage in hospitals, clinics, and other settings[1][4].

5. What are the major drivers of the halobetasol propionate market?

Major drivers include the increasing prevalence of dermatological conditions, advancements in formulations, and growing healthcare expenditure[2][4].

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.